NeuroDerm, Ltd.

In an unusual move, three US Food and Drug Administration complete response letters related to manufacturing issues were announced in the same week, all relating to very different products: a gene the

While many many Japanese firms have shifted much of their commercial and R&D focus to the US, several have recently faced development setbacks that could affect their mid-term outlook in this huge mar

The month of June could be among the busiest for US FDA approvals in 2024 to date, thanks to a stacked user fee goal date calendar that features nine novel agents and 13 potential new indications, acc

The global market for transdermal patch products, which is divided into five segments – cardiovascular disease, neurological disorders, hormone replacement therapies, pain management and genitourinary